PBYI
NASDAQ · Biotechnology
Puma Biotechnology Inc
$7.74
-2.03 (-20.78%)
Open$8.64
Previous Close$9.77
Day High$8.66
Day Low$7.59
52W High$11.50
52W Low$4.58
Volume—
Avg Volume397.9K
Market Cap422.23M
P/E Ratio15.80
EPS$0.52
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-29.6% upside
Current
$7.74
$7.74
Target
$5.45
$5.45
$2.99
$5.45 avg
$6.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 245.95M | 245.82M | 42.11M |
| Net Income | 33.51M | 30.14M | 7.89M |
| Profit Margin | 13.6% | 12.9% | 18.7% |
| EBITDA | 51.95M | 49.33M | 13.15M |
| Free Cash Flow | — | — | 4.76M |
| Rev Growth | +0.1% | +0.1% | +7.6% |
| Debt/Equity | 0.17 | 0.17 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |